Showing results (81-90 of 113) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsAlain C Mita, Louis J Denis, Eric K Rowinsky, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectantNeal J Meropol, Robert A Somer, John Gutheil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignanciesQuincy S C Chu, Garry Schwartz, Johann de Bono, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.Clinical Pharmacology and Therapeutics|May 16, 2002
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould, Nicholas H G Holford, Jan H M Schellens, et al.The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancerAnthony W Tolcher, Desiree Hao, Johann de Bono, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesHeinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, et al.American Journal of Clinical Oncology|August 3, 2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancersGhassan K Abou-Alfa, Eric K Rowinsky, Yehuda Z Patt, et al.Pageof 12